Form 4: Director Catherine Mazzacco Receives RSU Grant at Sight

Director Catherine Mazzacco was granted 28,261 restricted stock units as part of the Sight Sciences, Inc. non-employee director compensation program.

Summary

• Director Catherine Mazzacco received a grant of 28,261 restricted stock units (RSUs) on June 4, 2026.
• The grant is valued at approximately $130,000 based on the closing price on the grant date.
• The RSUs are scheduled to vest on the earlier of June 4, 2027, or the date of the 2027 annual meeting of stockholders.
• Vesting is contingent upon the director's continued service on the board.
• Following this transaction, the director's total beneficial ownership includes 69,276 shares held directly and 37,492 shares held in an irrevocable trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized compensation practice under the company's established non-employee director program.

Negatives

• None identified; this is a routine compensatory disclosure.

Risks

• Vesting is subject to continued service as a director, creating a dependency on board tenure.

Future Outlook

The filing does not provide forward-looking financial guidance for the company, focusing solely on director equity compensation.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard governance practice in the medical device and biotechnology sectors to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard corporate governance practices for publicly traded companies of similar market capitalization.
• The vesting period of approximately one year aligns with typical annual director compensation cycles observed in the healthcare industry.

Related Party Transactions

• The reporting person holds shares through the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensatory grant.

Next Steps

• Vesting of the RSU grant on June 4, 2027, or the 2027 annual meeting date.

Key Dates

Keywords

Sight Sciences, SGHT, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units